Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pioglitazone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    193 result(s) found for: Pioglitazone. Displaying page 7 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2012-004827-19 Sponsor Protocol Number: NN9535-3626 Start Date*: 2013-10-01
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BG (Completed) PT (Completed) ES (Completed) HU (Completed) CZ (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2011-000656-42 Sponsor Protocol Number: 3102-006-10 Start Date*: 2011-04-08
    Sponsor Name:MSD Finland Oy
    Full Title: A 66-Week Extension to: A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding, Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients with Type 2 Diabetes Mellitus and Ina...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004625-25 Sponsor Protocol Number: NN9068-4056 Start Date*: 2014-08-29
    Sponsor Name:Novo Nordisk A/S
    Full Title: A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) in subjects with type 2 diabetes mellitus using two different titration algorithms
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) AT (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-001596-48 Sponsor Protocol Number: NN9068-4229 Start Date*: 2016-03-29
    Sponsor Name:Novo Nordisk A/S
    Full Title: A clinical trial comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FI (Completed) HU (Completed) ES (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001222-27 Sponsor Protocol Number: EU-IIT-006 Start Date*: 2007-11-06
    Sponsor Name:Imperial College London
    Full Title: The effect of Pioglitazone on vascular and ventricular function in people with type 2 diabetes PICCOLA
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    9.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003843-36 Sponsor Protocol Number: H8O-US-GWCO Start Date*: 2008-09-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Trial Comparing Exenatide with Placebo in Subjects with Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-004112-13 Sponsor Protocol Number: 33100 Start Date*: 2009-06-26
    Sponsor Name:Nottingham University
    Full Title: PPAR-gamma: A noval therapeutic target for asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001283-22 Sponsor Protocol Number: CL3-00780-150 Start Date*: 2011-07-13
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.)
    Full Title: International follow-up study, after the investigational drug exposure in diabetic patients previously included in the REGULATE trial (benfluorex versus pioglitazone).
    Medical condition: Type II diabetes The medical condition investigated in the REGULATE trial (CL3-00780-148) was type II diabetes. The applied CL3-00780-150 trial, REGULATE follow-up study, is thus performed in d...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003614-27 Sponsor Protocol Number: GIA-DAP-16-005 Start Date*: 2017-08-16
    Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
    Full Title: Study on the effect of dapagliflozin on myocardial insulin sensitivity and perfusion (DapaHeart)
    Medical condition: TYPE 2 DIABETES
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000823-15 Sponsor Protocol Number: DIASA3 Start Date*: 2019-10-18
    Sponsor Name:Oslo University Hospital
    Full Title: Glucose metabolism in South Asian women with impaired glucose tolerance or impaired fasting glucose. DIAbetes in South Asians – DIASA 3 A 12-week intervention trial with oral antidiabetic medicati...
    Medical condition: Pre-diabetes in women of South Asian ethnicity. Women of South Asian ethnicity with previous gestational diabetes, where pre-diabetes in the form of impaired glucose tolerance or impaired fasting ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10036481 Pre-diabetes LLT
    Population Age: Adults Gender: Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000624-16 Sponsor Protocol Number: LOEWE_B4 Start Date*: 2011-11-28
    Sponsor Name:Justus Liebig Universität Gießen
    Full Title: Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome Male infertility with infection and inflammation -MIBIE-
    Medical condition: infertility and inflammatory urogenital diseases as a result of the metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10046694 Urogenital disorder PT
    14.0 10027433 - Metabolism and nutrition disorders 10052066 Metabolic syndrome PT
    14.0 10038604 - Reproductive system and breast disorders 10021926 Infertility PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004227-19 Sponsor Protocol Number: 3180A1-103-WW Start Date*: 2006-02-08
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: A 4-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE PRELIMINARY EFFICACY, SAFETY, AND PHARMACOKINETICS OF PPM-204 ADMINISTERED ORALLY TO TREATMENT-NAÏVE SUBJECT...
    Medical condition: Newly diagnosed Type 2 Diabetic Mellitus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004216-70 Sponsor Protocol Number: BM17864 Start Date*: 2007-01-30
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A randomized, double-blind, parallel group, placebo-controlled (with open-label active comparator arm), dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003897-87 Sponsor Protocol Number: 3180A1-200-WW Start Date*: 2007-06-19
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF PPM-204 IN SUBJECTS WITH TYPE 2 DIABETES.
    Medical condition: Subjects with type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006766-21 Sponsor Protocol Number: MINI-SPIOMET Start Date*: 2022-09-02
    Sponsor Name:Hospital de Girona Dr. Josep Trueta
    Full Title: Towards a treatment for accelerated maturation in girls testing spiomet in a randomised placebo controlled, multicentre study.
    Medical condition: Girls with advanced puberty and accelerated bone maturation. Polycystic Ovary Syndrome (PCOS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10014054 Early puberty LLT
    Population Age: Children, Under 18 Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005771-10 Sponsor Protocol Number: NN1250-3668 Start Date*: 2009-08-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 26 week randomised, controlled, open label, multicentre, multinational, three-arm, treat to target trial comparing efficacy and safety of three different dosing regimens of either Soluble Insulin...
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-000750-13 Sponsor Protocol Number: 1218.40 Start Date*: 2008-06-30
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.
    Medical condition: Patients with type 2 Diabetes Mellitus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) SE (Completed) AT (Completed) SK (Completed) DE (Completed) ES (Completed) GB (Completed) CZ (Completed) BE (Completed) HU (Completed) IT (Completed) GR (Completed) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012140-16 Sponsor Protocol Number: 28431754DIA3008 Start Date*: 2010-01-06
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ 28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
    Medical condition: Type 2 diabetes mellitus and history or high risk cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    19.0 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) HU (Completed) EE (Completed) CZ (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004864-29 Sponsor Protocol Number: F3Z-EW-IOPJ Start Date*: 2008-02-13
    Sponsor Name:Eli Lilly and Company
    Full Title: A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) GB (Completed) BE (Completed) SK (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005192-18 Sponsor Protocol Number: A5351022 Start Date*: 2007-03-15
    Sponsor Name:Pfizer Ltd.
    Full Title: A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABET...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) SK (Completed) SE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 12:12:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA